ArticleJournal of oncology2010
Progress on antiangiogenic therapy for patients with malignant glioma.
Article in Journal of oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- Pathophysiological roles of integrins in gliomas from the perspective of glioma stem cells.Frontiers in cell and developmental biology · 2022Review
- Role of Polymeric Local Drug Delivery in Multimodal Treatment of Malignant Glioma: A Review.International journal of nanomedicine · 2021Review
- Glioblastoma: Targeting Angiogenesis and Tyrosine Kinase Pathways.Novel approaches in cancer study · 2020Article
- Human Glioma Migration and Infiltration Properties as a Target for Personalized Radiation Medicine.Cancers · 2018Review
- MRI Monitoring of Cerebral Blood Flow after the Delivery of Nanocombretastatin across the Blood Brain Tumor Barrier.Journal of nanomedicine & nanotechnology · 2018Article
- Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials.Oncotarget · 2017Article
- Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma.Journal of neuro-oncology · 2017Article
- Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes.International journal of nanomedicine · 2017Article
- Defining differential roles for microglia and infiltrating macrophages in the growth and neovascularization of glioma.Translational cancer research · 2016Article
- Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes.Oncotarget · 2016Article
- Direct contact with perivascular tumor cells enhances integrin αvβ3 signaling and migration of endothelial cells.Oncotarget · 2016Article
- Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials.Molecular and clinical oncology · 2016Article
- Diagnostic and prognostic value of a disintegrin and metalloproteinase-17 in patients with gliomas.Oncology letters · 2014Article
- A microRNA Link to Glioblastoma Heterogeneity.Cancers · 2012Article
- Collagen IV and CXC chemokine-derived antiangiogenic peptides suppress glioma xenograft growth.Anti-cancer drugs · 2012Article
- Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma.Histology and histopathology · 2012Review
- Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin α6β1 in glioblastoma.Cancer research · 2012Article
- Glioblastoma cell-secreted interleukin-8 induces brain endothelial cell permeability via CXCR2.PloS one · 2012Article
- Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.Journal of oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Glioblastoma (GBM) is the most common primary brain tumor occurring in America. Despite recent advances in therapeutics, the prognosis for patients with newly diagnosed GBM remains dismal. As these tumors characteristically show evidence of angiogenesis (neovascularization) there has been great interest in developing anti-angiogenic therapeutic strategies for the treatment of patients with this disease and some anti-angiogenic agents have now been used for the treatment of patients with malignant glioma tumors. Although the results of these clinical trials are promising in that they indicate an initial therapeutic response, the anti-angiogenic therapies tested to date have not changed the overall survival of patients with malignant glioma tumors. This is due, in large part, to the development of resistance to these therapies. Ongoing research into key features of the neovasculature in malignant glioma tumors, as well as the general angiogenesis process, is suggesting additional molecules that may be targeted and an improved response when both the neovasculature and the tumor cells are targeted. Prevention of the development of resistance may require the development of anti-angiogenic strategies that induce apoptosis or cell death of the neovasculature, as well as an improved understanding of the potential roles of circulating endothelial progenitor cells and vascular co-option by tumor cells, in the development of resistance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.